Conference Coverage

Do Patients on Anti-Obesity Drugs Decrease Alcohol Use?


 

FROM OBESITY WEEK 2024

Mechanisms Appear Both Biological and Behavioral

During the discussion, Cardel said that qualitative assessments with participants suggest that there are at least two mechanisms behind this phenomenon: One biological and the other intentional.

“What we hear from them is twofold, one, particularly amongst those folks on GLP-1 medications, we’re hearing that physiologically, they feel different with the medications, that their cravings for alcohol are decreased, and that when they do choose to drink that there’s often a very much a negative reinforcement ... I’ve had a patient tell me, ‘I used to be able to have two or three margaritas, and maybe I didn’t feel like the best I’d ever felt in the morning, but I was okay. And now if I have two or three drinks, I will be throwing up for 5 hours, and it’s the worst hangover I’ve ever had in my life.’ And so it very much creates that negative reinforcement loop.”

But at the same time, “folks who are coming to us and seeking these medications are very much on a on a health-based journey. That’s what they tell us. The majority of our patients are there to improve their health. We rarely hear about the vanity or aesthetic part of it. So perhaps it’s that, in terms of trying to improve their health, they’re also trying to reduce their alcohol consumption, either just for their overall health or also as a means of trying to decrease their overall calorie consumption.”

In future research, Cardel said, “we want to examine whether the anti-obesity medications are more successful at reducing alcohol use compared to non-pharmacological weight management interventions, as we know that people often reduce their alcohol consumption on a weight management journey as a means of prioritizing their calories for food and decreasing the calories from alcohol.”

Cardel and all the study coauthors were employees and shareholders at WeightWatchers at the time the research was conducted. Skelton is editor in chief of the journal Childhood Obesity.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

Humans and Carbs: A Complicated 800,000-Year Relationship
MDedge Endocrinology
Cardiovascular Disease 2050: No, GLP-1s Won’t Save the Day
MDedge Endocrinology
Should the Body Roundness Index Replace BMI?
MDedge Endocrinology
ATA: Updates on Risk, Diagnosis, and Treatment of Thyroid Cancer
MDedge Endocrinology
Can We Repurpose Obesity Drugs to Reverse Liver Disease?
MDedge Endocrinology
Coming Soon: A New Disease Definition, ‘Clinical Obesity’
MDedge Endocrinology
Topiramate Plus Metformin Effective for Weight Loss in PCOS
MDedge Endocrinology
Weight Loss Interventions Improve Key Features of PCOS
MDedge Endocrinology
Knowledge Gaps About Obesity Medicine Seen in Primary Care
MDedge Endocrinology
Treating Obesity May Reduce Pelvic Organ Prolapse Risk
MDedge Endocrinology